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Abstract 
Current microbial inhibition strategies based on planktonic bacterial physiology have been 
known to have limited efficacy on the growth of biofilms communities. This problem can be 
exacerbated by the emergence of increasingly resistant clinical strains. All aspects of biofilm 
measurement, monitoring, dispersal, control and inhibition are becoming issues of increasing 
importance. Biosurfactants have merited renewed interest in both clinical and hygienic 
sectors due to their potential to disperse microbial biofilms in addition to many other 
advantages.  The dispersal properties of biosurfactants have been shown to rival that of 
conventional inhibitory agents against bacterial and yeasts biofilms. This makes them 
suitable candidates for use in new generations of microbial dispersal agents and for use as 
adjuvants for existing microbial suppression or eradication strategies. In this review we 
explore aspects of biofilms characteristics and examine the contribution of biologically 
derived surface-active agents (biosurfactants) to the disruption or inhibition of microbial 
biofilms. 
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Introduction 
Microorganisms in general gravitate towards solid surfaces forming biofilms as a strategy to 
protect themselves from environmental challenges. Such deposition and subsequent biofilm 
formation is a phenomenon that happens naturally and is usually part of the microorganisms’ 
strategy to protect themselves from external toxic factors (Pereira et al. 2007).  They have 
the ability to sense their own cell density, communicate and behave as a population through 
cell to cell signalling, a phenomenon known as quorum-sensing (Liu et al. 2012). This 
behaviour has been documented for some time in microbial biofilm formations (Davies 2003) 
and is dependent on the nutritional/environment and the maturation stage of development of 
the microorganisms. Microbial biofilms represent a distinct bacterial physiology characterised 
by a multicellular phenotype that is fundamentally different from planktonic bacteria.  They 
have been implicated in chronic and recalcitrant healthcare associated infections (Dowd et 
al. 2008), the dissemination of community acquired diseases (Stewart et al. 2012), effective 
hygienic processing, increased failure rate of anti-infective therapy (Bueno, 2014) and 
marine water and electronics environments (Lourenco et al. 2011). Biofilms that are 
composed of one species are relatively rare in the majority of the natural environment; rather 
microorganisms tend to be found in complex multispecies communities associated with 
surfaces (Stoodley et al. 2002). 
Until recently the differences between planktonic and biofilm physiologies seemed 
inconsequential. Standard bacterial inhibition tests were almost exclusively based on 
planktonic bacterial physiology and not the biofilm physiology even though these conditions 
were not readily observed in the natural environment. The standard planktonic bacterial 
physiology is typically exemplified by free-living single bacteria with optimal nutrition, gas 
exchange and agitation (typically 250rpm) (Bueno 2014; Kotulova and Slobodnikova, 2010).
In contrast, the biofilm physiology has multicellular differentiation, multicellular 
communication, internal architecture and rudimentary fluid transport systems (Girard et al. 
2010; Leis et al. 2005). More importantly for in-vitro testing procedures, biofilms have 
variable levels of nutrients, gas exchange, little or no agitation and therefore slower growth. 
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This difference in bacterial physiology can be critical especially in clinical situations where 
there is a higher production of virulence factors in pathogens such as Pseudomonas 
aeruginosa (Croda-García et al. 2011). In the biofilm physiology these pathognes can be one 
to three orders of magnitude more resistant to dispersal/inhibition by conventional 
chemotherapy than their planktonic counterparts of the same species (Girard et al. 2010; 
Olson et al. 2002; Sepandj et al. 2004). This has been demonstrated in recent experiments 
on biofilm formation during peritoneal dialysis, where all the antibiotics tested were effective 
in laboratory MIC tests but (with the exception of gentamicin) lost their efficacy against 
Staphylococcus aureus biofilms (Girard et al. 2010). Globally, methicillin resistant 
Staphylococcus aureus (MRSA) is a serious problem due to limited efficacy of antibiotic 
options, hospital hygiene and the resistance of biofilm associated clinical strains (Samadi et 
al. 2012). Some biofilms also undergo phenotypic change as a result of chemotherapy 
resulting in increased resistance. 
New insights into biofilm physiology have now enabled researchers to design more 
effective bacterial inhibition/dispersal strategies. There are two main inhibitory strategies, 
based on the formulation of new antibiofilm compounds and the construction of biofilm 
resistant surfaces (Villa and Cappitelli, 2013). 
Some of the most promising candidates for the inhibition of bacterial biofilms have 
come from biological surface-active agents (biosurfactants) (Kiran et al. 2010; Pradhan et al. 
2013). Many of these have been reported to have anti-adhesive, antimicrobial and biofilm 
disruption properties (Rodrigues et al., 2006a,b,c; Rodrigues et al., 2007). Enzymatically 
synthesized surfactants such as lauryl glucose have also been reported to be effective 
against fungal and bacterial biofilms (Dusane et al. 2010). 
Biosurfactants are a heterogeneous group of amphiphilic compounds produced 
mainly by microorganisms that accumulate at the interface between liquid phases and 
therefore reduce surface and interfacial tension. They have been recognised for some time 
in a diverse array of potential applications in a wide range of industries including agriculture, 
food, cosmetic, pharmaceutical and petroleum industries (Banat et al. 2010). The surface 
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and interfacial tension reducing properties of surfactants provide excellent detergency, 
emulsification, foaming and dispersing traits, making them some of the most versatile 
products in chemical processes (Desai and Banat 1997). They are highly sought after 
molecules due to their specificity, low toxicity, high biodegradability, widespread applicability 
and effectiveness at extremes of pH and temperature (Muthusamy et al. 2008).  
   Several strands of research have demonstrated that under certain testing conditions 
biosurfactants can be more effective than many traditional biofilm inhibition and or disruption 
strategies (Epstein et al. 2011).  There have been many reviews of biosurfactants and their 
potential applications in environmental and biomedical related areas (Neu 1996; Banat et al. 
2010; Banat et al. 2000). There has been however renewed interest in biosurfactants in 
relation to healthcare associated infections (Krasowska 2010). In addition, the rapid pace of 
advances in biofilm inhibition, control/disruption and the emergence of biofilms as potential 
reservoirs for the dissemination of disease have necessitated a review of the current state of 
the art on biofilms measurements and potentially effective biosurfactants against microbial 
biofilms. 
   To our knowledge the area of biofilms and role of biosurfactants within is becoming 
an increasingly important topic of research yet has not been the subject of a review article. In 
this review therefore we examine biofilms characteristics, monitoring and quantification and 
the main classes of current biosurfactants in use, their contribution to the dispersal or 
inhibition of biofilms, their scope and efficiency, quantification of this dispersal/inhibition and 
the sources and limitations of their uses. 
 
The nature and functions of biosurfactants  
Biosurfactants are amphiphilic compounds of biological origin containing a hydrophilic region 
(polar or non-polar) and a hydrophobic region (lipid or fatty acid).  The hydrophilic group is 
the base of the International Union of Pure & Applied Chemistry nomenclature i.e. those 
biosurfactants containing rhamnose are described as rhamnolipids; while those containing 
sophorose are sophorolipids and those generally containing a carbohydrate moiety including 
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the previously mentioned two types are described as glycolipids. Other lipopeptide 
biosurfactants contain a lipophilic hydrocarbon chain described as hydrophobic and a polar 
or hydrophilic part which is usually composed of a string of amino acids. 
 
Function  
Biosurfactants have been identified in many biological processes as the components of 
cellular metabolism, motion and defence. They are found in great abundance in bacteria, in 
biofilms, as quorum sensing molecules, lubricants, promoting the uptake of poorly soluble 
substrates, as immune modulators, virulence factors, secondary metabolites and 
antimicrobial compounds (Fracchia et al. 2012). In a review by Neu (1996) it has also been 
proposed that biosurfactants act as important molecules for interfacial processes, 
conditioning the microbial cell surface, interfaces and surfaces with which the 
microorganisms interact. These biosurfactants can be found in greater concentrations in the 
layers of cells associated with movement and hydration although they can have an 
intracellular location.  
   Biosurfactants’ also have important roles in the dissolution and accessibility of oil 
molecules especially for oil degrading microorganisms; adhesion to hydrocarbons as a result 
of the emulsification of water-insoluble substrate compounds; the de-adhesion from 
interfaces; facilitating the in gliding of bacteria through wetting interfaces. Such surface 
active molecules can also have a role in enhancing the interaction between microorganisms 
and all the natural organic hydrophobic compounds interfaces including plant and animal 
derived polymeric compounds and microbial exopolysaccharides (Neu 1996). The role of 
bacterial biosurfactants has been extensively studied in Pseudomonas where they are 
known to promote colonisation and migration-dependent structural development (Pamp and 
Tolker-Nielsen 2007).   
   Other roles for biosurfactants including biocidal activity have been reported. This is 
mainly related to the effects of the lipidic moiety against eucaryotic cells. This has also been 
reported to lead to toxicity, lysis, pyrogenicity, mitogenicity and immunogenicity among other 
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effects (Wicken and Knox 1980). Lysis of red blood cells has been used as a selection 
criterion for microorganisms producing biosurfactants (Satpute et al. 2009).  Finally human 
derived biosurfactants have recently received increased attention because of their role in 
immunity and defence (Gakhar et al. 2010). 
 
Measurements of biosurfactants physical properties 
There are many methods employed to test physico-chemical properties of biosurfactants. 
These are very important for base line comparisons. The standard tests are based on the 
physical properties of biosurfactants such as measurement of reduced surface tension. 
Other tests measure the critical micelle concentration (CMC) which is the concentration of 
surfactants above which micelle formation occurs. The CMC for example of sodium dodecyl 
sulphate in water (with no other additives or salts) at 25°C and, atmospheric pressure, is 
8x10-3mol/l. The emulsification index (E24 or EI24) is another method used to characterize 
a biosurfactants’ ability to form a stable emulsion with a hydrophobic phase. The hydrophilic 
phase in this instance is usually water which, can be mixed with Kerosene and the 
biosurfactant, shaken vigorously and allowed to stand for 24 hours. The percentage 
emulsion of the water solution in kerosene is reported as the E24 or EI24 (Desai and Banat 
1997). Other characterisation methods in use are the oscillating jets and the maximum 
bubble pressures measured in the presence of the surface active compounds.   
 
Conditions for monitoring biofilm formation  
There is no standard laboratory method for quantifying biofilms though there are preferred 
methods.. In the past, planktonic bacterial inhibition assays have had to have strictly defined 
experimental criteria in order to reduce variation in results and increase confidence in 
antibiotic comparisons. However, these tests do not adequately represent different bacterial 
growth physiologies such as that in biofilms. The first biofilm tests were very similar to these 
planktonic experiments and created the impression that biosurfactants were weak 
counterparts of conventional inhibitory agents. Later, research into biofilm inhibition showed 
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that these tests did not give an accurate reflection of the efficacy of biosurfactants. Today’s 
biosurfactant tests are more accurate and try to represent the in-situ environment as much 
as possible. Many of these tests are based on pre-coating a surface with a known amount of 
biosurfactant overlaid with microbial biofilm (O'Toole 2011). This can be alternated with 
overlaying pre-existing biofilms with the test substance. 
   Since the biofilm physiology is distinct from the planktonic physiology, biofilm 
experimental conditions have had to be adjusted accordingly. In terms of temperature the 
biofilm cultivation is carrier out at the optimal temperature for biofilm growth of a particular 
species which may not be the same as the optimal temperature for planktonic growth, this 
could mean that biofilm cultivation may be at 20°C (even for clinical specimens) whilst others 
may be at 10°C in the cases of some environmental biofilms (Quinn et al. 2012). 
 In terms of nutrition, it is common practice for biofilms to be cultivated in a dilution of the 
media that is used for planktonic cultivation, this is usually ½ to 1/5th of standard 
concentrations reflecting the sub-optimal conditions of biofilm growth, however this practice 
is not universally applicable (Stepanovic et al. 2004).  
Since biofilms also grow slower that optimised planktonic conditions, the typical cultivation 
period for biofilms can vary from 4 hours to 3-4 days or even 7-10 days in the case of slower 
growing environmental biofilms (Quinn et al. 2012; Stepanovic et al. 2007). Agitation 
considerations are equally important. In the earliest biofilm growth assays it was thought that 
environments of high sheer stress were necessary. However more recent research has 
shown that environments of high agitation are not necessary for all biofilm growth and these 
growth conditions can be considered strain specific. Rather biofilm tests are typically 
conducted in almost static environments or environments of minimum perturbation (O'Toole 
2011; Stepanovic et al. 2007). 
   The standard inoculation density of microorganisms also differs greatly from standard 
planktonic tests. For planktonic MIC tests organisms are seeded at a density of 1x106 /ml of 
fresh cells taken from the logarithmic stage of growth. In biofilm cultivation seeding densities 
are typically a 1/100 dilution of a stationary phase culture (McLaughlin and Hoogewerf 2006; 
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Quinn et al. 2012). Some researchers use biofilm induction agents such as high glucose or 
alcohol to aid biofilm formation but these may add unknown variables to the assay making 
the final biofilm data difficult to interpret. 
   Recently, Lourenco and co-workers (2014) published the results of an initiative to 
establish “minimum information about a biofilm experiments” (MIABiE) which is a project 
partly funded by EU grants to find a scientifically adequate procedures to document biofilm-
related data. They asserted that this could be achieved through ensuring a set of minimum 
information that should be reported to guarantee the independent verification and 
interpretation of experimental results in a way that would allow their integration with biofilm 
related information generated by other fields. 
 
Surfaces for the quantification of biofilm growth 
The physiochemical properties of substrates used for biosurfactant evaluations can affect 
the nature of biofilm adhesion, the subsequent biofilm architecture in the case of 
monocultures or the selection of the microbial species which colonise in the case of mixed 
and environmental biofilms. Biofilms also express different repertoires of proteins or 
adhesion characteristics depending on the surface characteristics of the substrate they are 
attached to (Stoodley et al. 2002). Hence the choice of surface for biofilm cultivation is very 
important and must be taken into account even when comparing the results of inhibitory 
tests. . 
   The different surfaces used in biofilm tests range from animate/inanimate, 
rough/smooth, hydrophobic/ hydrophilic and liquid/air/liquid etc. Laboratory cultivation of 
biofilms can be conducted on many surfaces including glass, plastic, metal, silicone and 
tissue models (O'Toole 2011). In more comprehensive assessments of the inhibition 
potential biosurfactants can be applied to a broad range of surfaces especially in clinical 
environments. Research into the efficacy of Pseudofactin II (a newly characterised 
biosurfactant) used many different surfaces such as glass, polystyrene and silicone to 
cultivate biofilms in combination with different bacterial strains in order to demonstrate its 
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wide efficacy (Janek et al. 2010 & 2012). In other research on biofilms of Salmonella, 
investigators used PVC and silicone (urethral catheters) as biofilm substrates to demonstrate 
the applicability of biosurfactants in the reduction of biofilm formation/attachment (Mireles et 
al. 2001). 
 
Quantification of biofilm inhibition/dispersal  
The Calgary Biofilm Device  
One of the first devices employed to measure biofilm inhibition/dispersal was the Calgary 
biofilm device (CBD) (Olson et al. 2002). This technique is widely used in flow tests for 
microbial biofilms (Rivardo et al. 2009; Girard et al. 2010; Rivardo et al. 2011). The 
cultivation chamber consists of a 96-well plate together with a lid that contains 96 peg 
projections (Figure 1). These pegs provide a maximum surface area for the growth of 
biofilms. The CBD has a typical seeding density of 1x104 to 1x106 bacteria per well or 
McFarland standard 1, a cultivation speed of ≥10rpm and an incubation period of 4-24 h 
depending on species and conditions (Girard et al. 2010). 
   Microbial biofilms are cultivated on test pegs projecting into a growth media, removed 
after a given time, washed and then inserted into wells containing an inhibitory/test 
substance. Mature biofilms can be subsequently detached from the pegs by ultrasonic 
treatment. The detached microbes can be enumerated by standard cultivation techniques or 
quantified by measuring their optical density at 650nm. The amount of bacterial inhibition of 
the biofilms is referred to as the minimal biofilm eradication concentration (MBEC). The 
MBEC represents the lowest dilution of inhibitory substance. If cultivation conditions require 
a greater circulation of media the lid of this plate can be modified to accommodate 12 media 
channels into which the 96 pins are extended.. In this manner 96 pins can be simultaneously 
exposed to a given culture (Ceri et al 1999) 
   Although the CBD was a welcome departure from planktonic based testing regimes 
and a step towards a more accurate portrayal of biofilm physiology; the method still relied on 
the final detection of viable planktonic microorganisms rather than directly measuring the 
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whole biofilm biomass.  It also assumes that bacteria from viable biofilms can immediately 
rejuvenate on agar or directly into culture broth. This is an important point in biofilm 
physiology since studies on the resuscitation of bacterial cells have shown that some 
microorganisms may still be viable in the biofilm but not immediately cultivatable especially 
after prolonged chemotherapy (Rollet et al. 2009). This is also important when considering 
the negative impacts of the selective pressure of chemotherapy on biofilm forming 
pathogens. In some cases it has been shown that severe chemotherapy can induce a viable 
but dormant pathogen that can resuscitate in more favourable conditions to contribute to the 
chronic character of a biofilm infection (Zhang 2014). 
   Finally, the CBD measures the amount of cells in a biofilm and not the biofilm 
biomass i.e. the biofilm + extra polymeric substances (EPS). However biofilm substances 
that are not cells can constitute a significant proportion of biofilms (Decho 2013). 
 
Biofilm growth within flow-through devices 
Biofilms can be analysed under flow conditions by a variety of methods including the CBD. 
However another flow system currently used to test biofilms is the BioFlux 200 system 
(Fluxion Biosciences Inc., South San Francisco, CA) (Benoit et al. 2010; Ding et al 2014; 
Chabane et al. 2014).One of the benefits of such a system is that it  is amenable to real-time 
analysis of the biofilm through automated image acquisition within specialized multi-well 
plates. In order to cultivate biofilms, microfluidic channels are primed with the culture 
medium at a specific rate. Each channel is seeded with an overnight culture with a cell 
density of 107 CFU. The biofilms are subsequently incubated at specific time and 
temperature levels in order for the bacterial cells to adhere. Once the biofilms have formed, 
planktonic cells are removed, and washed. The biofilm growth can then be recorded using a 
phase contrast or fluorescence microscope (Ding et al. 2014). 
 
In-vitro Biofilm formation in a 8 well chamber 
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Another variation of biofilm chamber growth is the use of an 8-well chamber slide. This 
method uses 200µL aliquots of mid-logarithmic cells diluted in fresh medium (1:2500 (v/v)). 
The medium can be replaced every 12h if the biofilm takes longer than 24h to grow or as 
needed to maintain bacterial viability (O’Toole 2011). 
   The resulting biofilms can be visualized by aspirating the medium and washing with 
saline. The viability of the biofilm cells is typically assessed by the addition of BacLight 
Live/Dead stain (O’Toole 2011). Additionally, EPS or pili in the biofilms can be visualized 
under SEM by dehydrating the sample in a graded series of alcohols and adding 
hexamethyldisilazane (HMDS) (Araujo et al 2003). 
 
Crystal violet quantification of biofilm growth 
One of the most commonly used methods to assess the effectiveness of biosurfactants and 
biofilm inhibitory agents is the crystal violet quantification of biofilm growth (O'Toole 2011). 
The technique involves the cultivation of a microbial biofilm in a 96-well (high bind PVC) 
plate, a rinsing step and final staining with 1% crystal violet. Biofilms are quantified by 
assessing the proportion of crystal violet bound to the biofilm biomass in control and test 
cultivations. The surfaces of high-bind 96 well plates were originally designed for ELISA 
tests and hence contain organically compatible high protein binding plastic (other types of 
PVC have different binding properties). This type of surface allows the binding of large 
molecules with ionic groups or large hydrophobic regions and permits a wide diversity of 
bacteria to form biofilms.  
   The advantages of this method of biofilm quantification is that dispersal/inhibition can 
be measured directly in-situ rather than extrapolated from viable planktonic microorganisms. 
The crystal violet stains the total biofilm biomass which includes EPS and extracellular 
proteins rather than just its component cells. There may be some variability in the results 
obtained from this test but this can be rectified by a higher number of replicates which is 
afforded by the 96-well plate. 
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Quantification of biofilm inhibition by direct analysis  
One of the simplest methods of biofilm quantification is by direct measurements of bacterial 
viability as directly proportional to biofilm dispersal (Rodrigues et al. 2004). This technique 
does not measure total biofilm biomass or biofilm adhesion, however it is a useful validation 
step for other methods. This quantification becomes more problematic for mixed bacterial 
populations and viable but non-cultivatable microorganisms. 
 
Bacterial Viability Quantification 
There are several viability dyes that are used to quantify biofilm. Most of these are based on 
DNA binding. These include two of the most widespread fluorescent dyes, propidium iodide 
which binds to DNA when the cell nuclear membrane is damaged fluorescing red and syto 9 
green which binds to DNA when the nuclear membrane is intact (Lehtinen et al. 2004). In the 
case of biofilms this quantification can be complicated by extracellular DNA but this might 
only apply in very dense biofilms. 
 
Digital quantification 
Fluorescent stains are easily quantified by digital technologies. This makes it easier to 
assess biofilm growth/dispersal. As mentioned above although this technique may be 
directly quantitative for bacterial monolayers or biofilms of several layers thick, there are still 
technical issues however with proportional measurements of complex multi-layered biofilms 
with all the associated dead spaces and channels.  
 
Other microscopic quantification 
Scanning electron microscopy (SEM) has proved to be a useful technique for pictorial 
representations of biofilms, however the preparation methods involved including successive 
dehydrations in alcohol and gold sputtering can fundamentally alter the composition and 
biofilm architecture of biofilms. More promising results have recently been obtained by the 
use of cryo-SEM (Alhede et al. 2012). As previously stated, the biofilm substrates used in 
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microscopic techniques have to be quite robust such as glass; however this may also have a 
role in determining the formation of the biofilm and cannot always be used in direct 
comparisons to the same biofilms growth on plastic or silicone. 
 
Biosurfactants as antibiofilm molecules 
One of the most common questions posed on the effects of biosurfactants on biofilms is why 
are there still biofilms when biosurfactants are powerful molecules mostly leading to biofilm 
inhibition? The current hypothesis is that surface active molecules play a major role in the 
development and maintenance of biofilms partly through the maintenance of water channels 
through the biofilm which enhances nutrients movements and gaseous exchange, and which 
ultimately leads to the dissociation of parts of the biofilm into planktonic mobile forms 
(Marchant and Banat 2012). However the current focus of research is the ability of 
biosurfactants to disrupt established biofilms and prevention of the development of new 
ones. Although there are diverse arrays of biosurfactants, this review focuses on those in 
current use or known for the ability to disrupt biofilms in-vitro (Table 1). 
 
Lipopeptides biosurfactant as disruptor molecules 
Lipopeptides are one of the largest groups of biosurfactants that can effectively disperse 
microbial biofilms. These generally referred to by their group name although they can be 
composed of three or more varieties of homologous or congeners molecules. This group 
includes surfactins, polymixins, fengycins and fusaricidins (Krupovic et al. 2007; Pecci et al. 
2010; Raza et al. 2009; Rivardo et al. 2009). Structurally lipopeptides are composed of a 
hydrophilic peptide attached to hydrophobic lipid or fatty acid. The peptides can either be 
aliphatic, branched or cyclic. Similarly, the lipids chains can vary in length and conformations 
ensuring a wide diversity of structures. Many of the current lipopeptides reported to 
inhibit/disperse biofilms originate from Bacillus or Paenibacillus (Kim et al. 2009; Price et al. 
2007; Quinn et al. 2012). 
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Polymyxins 
Polymyxins, are a class of non-ribosomally synthesized cyclic lipopeptides. They are 
generally produced as secondary metabolites of Bacillus or similar species (Price et al. 
2007). Their typical structure is that of a cyclic polypeptide attached to a fatty acid tail. They 
can also contain exotic bacterial amino acids such as 2, 4, diaminobutyric acid (DAB) (Figure 
2A). Polymyxins are known have a limited clinical spectrum of inhibition in the treatment of 
Gram negative infections. There are several commercially available formulations of 
polymyxins including Colistin (polymyxin E) (Falagas and Kasiakou 2005), Neosporin and 
Polymyxin B which can be supplied as polymyxin B sulphate (a mixture of polymixins) (He et 
al. 2010). Polymyxin can also be combined with trimethoprim for eye conditions (Polytrim) 
and with neomycin and bacitracin to make triple antibiotic ointment Neosporin. 
Polymyxins are the last drug of choice in some infections and are often prescribed 
with caution due to fears of their toxicity however this estimation has been reappraised in the 
light of more rigorous testing (Arnold  et al. 2007). Polymyxins are prescribed intestinally or 
topically as cream or powders in most cases of multi drug resistant Acinetobacter baumannii, 
Klebsiella pneumoniae, and Pseudomonas aeruginosa (Falagas and Kasiakou 2006; Milletli 
Sezgin et al. 2012). Polymyxin has been reported to reduce biofilms of Pseudomonas 
aeruginosa at concentrations of 20µg/ml by 99% in a 12 hour time period and almost 
completely over 24 hours (Jass and Lappin-Scott 1996). However these results are based 
on the viability of bacteria and not their dispersal; although it was noted that bacterial cells 
displayed an altered morphology. Polymyxin E (colistin) is recommended as an early 
aggressive therapy to delay the onset of chronic P. aeruginosa infection (which frequently 
forms biofilms) or intermittent colonization in cystic fibrosis patients, a combination of oral 
ciprofloxacin with colistin inhalation (Doring et al. 2000). 
Polymyxin D1 has been shown to be effective against mixed bacterial biofilms, 
however our earlier work has shown this compound was found in combination with 
fusaricidin and surfactin in undefined ratio’s (Quinn et al. 2012). This complex of 
biosurfactants was also reported to inhibit the formation of biofilms of both Gram positive 
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bacteria such as Staphylococcus aureus, Streptococcus bovis, Bacillus subtilis and 
Micrococcus luteus and Gram negative bacteria such as Pseudomonas aeruginosa.  Most 
interestingly the biosurfactants were able to inhibit the formation of mixed species biofilms 
such as self-assembling marine biofilm (SAMB) in co-incubation assays by 99.3% and 
disrupt previously established mixed SAMB by 72.4% (Quinn et al. 2012).  
   The mechanism of action of polymyxins on bacterial biofilms remains largely 
undefined.  However the mechanism of action on planktonic bacteria is proposed to be 
related to their high affinity for lipopolysaccharide (LPS) (Domingues et al. 2012).  This 
induces LPS aggregation increasing the surface charge of LPS leading to internalization and 
binding to the bacterial phosphatidylglycerol-rich membrane leaflets which in turn induces 
leakage of cellular contents (Domingues et al. 2012).   
 
Fengycin-like lipopeptides 
Fengycin-like lipopeptides are derived from Bacillus subtilis and Bacillus licheniformis.  
These are cyclic lipopeptides containing 8-10 amino acids linked to a beta hydroxy fatty acid 
(Figure 2B).  Fengycin-like peptides have also been reported to be involved in the inhibition 
of biofilms (Xu et al. 2013) causing up to 90% dispersion of Gram positive S. aureus biofilms 
and up to 97% dispersion of Gram negative E. coli biofilm  (Rivardo et al. 2009) . 
 
Putisolvin 
Putisolvin is a cyclic lipodepsipeptide isolated from Pseudomonas putida. This has been 
characterised in two forms, putisolvin I and putisolvin II. This biosurfactant has a four 
member cyclic peptide; the valine residue in putisolvin I being substituted by a leucine or 
isoleucine in putisolvin II. (Figure 2C ) (Dubern et al. 2006). Although Putisolvin is involved in 
biofilm formation by Pseudomonas putida these surfactants have also been shown to be 
effective dispersal agents in pre- and post-addition to biofilms of other Pseudomonas sp. 
strains (Kuiper et al. 2004). 
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Pseudofactin 
Pseudofactin is a cyclic lipodepsipeptide derived from P. fluorescens. The structure of 
Pseudofactin is based on that of a palmitic acid attached to the terminal amino group of an 
eight amino acid peptide chain. The C-terminal carboxylic group of the last amino acid forms 
a lactone with the hydroxyl of third amino acid which is a threonine (Figure 2D). Pseudofactin 
II has been reported to be 36-90% effective against the adhesion of five species of bacterial 
biofilms on glass, polystyrene and silicone substrates. These strains include Enterococcus 
faecalis, Escherichia coli, Staphylococcus epidermidis, Enterococcus hirae and Proteus 
mirabilis. Similar inhibition of adhesion (92-99%) was reported on yeast biofilms of Candida 
albicans at concentrations of 0.5 mg/ml (Janek et al. 2012).  
   Pseudofactin has been documented to produce an effective dispersal of 26-70% on 
pre-existing biofilms grown on untreated surfaces and has been shown to cause a marked 
inhibition of the initial adhesion of E. hirae, E. coli, E. faecalis and C. albicans to silicone 
urethral catheters. Total growth inhibition of S. epidermidis  has been observed at the 
highest concentration tested (0.5 mg/ml), which causes a partial (18-37%) inhibition of other 
bacteria, a 8-9% inhibition of C. albicans yeast growth and a 99% prevention of adhesion  
(Janek et al. 2012). 
 
Surfactin  
Surfactins are one of the most powerful biosurfactants originally isolated from Bacillus 
subtilis and consist of a cyclic peptide heptamer connected to a 13-15 carbon, beta-hydroxy 
fatty acid chain (Figure 3A). Unfortunately surfactins can also be indiscriminately cytotoxic 
with haemolytic activities due to its interactions with cellular membranes (D'Auria et al. 
2013). They have been reported to inhibit the growth of biofilms of Salmonella sp. cultivated 
on PVC microtitre wells and urethral catheters (Mireles et al. 2001). They have been 
observed to cause a rippling effect in lipid bilayers perhaps indicating a clue to the 
mechanism of biosurfactant action or biofilm permeability or integrity (Brasseur et al. 2007) 
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most likely through the formation of some kind of channels within the biofilm increasing 
penetrability. 
 
Complexes of lipopeptides  
Although many lipopeptides have been characterised for experimental purposes as pure 
compounds they are in fact usually associated with groups of similar compounds.  This is 
reflected in their availability as minimally purified preparations. Siram and co-workers (2011) 
reported on one such complex of lipopeptide biosurfactants produced by a heavy metal 
tolerant strain of Bacillus cereus. This surfactant effectively dispersed biofilms at an active 
dose of 0.150μg and was noted to be very tolerant of fluxes in pH, temperature and NaCl, in 
addition to being resistant to high levels of iron, lead and zinc whilst maintaining 
antimicrobial and biofilm dispersal activity. Another complex of surfactants isolated from 
Paenibacillus polymyxa. PPE was found to consist of polymyxin D1, fusaricidin B and traces 
of surfactin (Deng et al. 2011; Quinn et al. 2012) (Figure 3 B & C).  
   A preparation containing 2mg/ml of such lipopeptides tested in one of our 
laboratories inhibited (87-98%) the formation of many Gram positive bacterial biofilms such 
as Staphylococcus aureus, Streptococcus bovis, Micrococcus luteus, Bacillus subtilis and 
also some Gram negative bacteria such as Pseudomonas aeruginosa (Quinn et al. 2012).  
More uniquely in terms of biofilm experiments, this combination of lipopeptides was effective 
against mixed environmental strains’ biofilms formation (99% inhibition) and up to 74% in 
pre-established biofilms. 
 
Synergy of lipopeptides with other inhibitors 
Lipopeptide biosurfactants have been combined with conventional antibiotics in an effort to 
produce synergistic inhibition effects.  Lipopeptides isolated from Bacillus licheniformis 
(strain V9T14) were reported by Rivardo and co-workers (2011) to have a synergistic effect 
against a mature 24-h uropathogenic E. coli (CFT073) biofilms when combined with 
ciprofloxacin, cefazolin, piperacillin, ceftriaxone, ampicillin, tobramycin and 
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trimethoprim/sulfamethoxazole. They concluded that some combinations led to total 
eradication of biofilm; however the antibiotics on their own had poor inhibitory activity 
(Rivardo et al 2011). 
 
Glycolipid biosurfactants as antibiofilm molecules 
Glycolipids consist of a carbohydrate attached to aliphatic or hydroxy-aliphatic acid.  These 
are one of the most studied groups of biosurfactants in other fields although they are 
underrepresented as agents of biofilm dispersal. 
 
Rhamnolipids  
Rhamnolipids consist of di- or mono-rhamnose sugars attached to a fatty acid chain (Figure 
3 D & E). Originally isolated from Pseudomonas aeruginosa, analogues are also produced 
by isolates of Burkholderia (Costa et al. 2011), Renibacterium salmoninarum, Cellulomonas 
cellulans, Nocardioides and Tetragenococcus koreensis (Abdel-Mawgoud et al. 2010).  
Rhamnolipids have been reported as a potential replacement to chemical surfactants for 
many uses in the oil and petroleum industries and in use for the bioremediation of oil 
contaminated environments (Marchant and Banat 2012a & b). They are frequently cited as 
inhibitors of bacterial growth although their capacity to inhibit biofilms however has not been 
as extensively documented. 
   Rhamnolipids are involved in biofilm formation in Pseudomonads sp. through the 
promotion of motility, the inhibition of attachment and degradation of the matrix maintaining 
channels throughout the biofilm for movement of water and oxygen (Boles et al. 2005; Davey 
et al. 2003). These biosurfactants were previously reported as antibacterial against 
Staphylococcus aureus, Mycobacterium sp, Bacillus sp, Serratia marsecens, Enterobacter 
aerogenes, Klebsilella pneumonia and against fungi such as Chaetomium globosum, 
Aureobacidium pullulans, Gliocladium virens, Botryhs cinerea and Rhizoclonia solanii 
(Benincasa et al. 2004; Haba et al. 2003). 
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   Rhamnolipids have also been shown to be effective against biofilms of Bordetella 
bronchiseptica (Irie et al. 2005).  The mechanism of biofilm inhibition is thought to be by the 
detachment of cells; however some unattached cells may still be viable. They have been 
reported to disrupt pre-formed biofilms such as Bacillus pumilus from the marine 
environment (on polystyrene microplates) resulting in a dispersal at sub-MIC concentrations 
and confirming ability to remove pre-formed biofilms (Dusane et al. 2010).  This was 
corroborated by scanning electron microscopy which showed that rhamnolipids removed 
biofilm-matrix components (Dusane et al. 2010). The effects of rhamnolipids on pre-formed 
biofilms of P. aeruginosa PAO1 generated in our laboratory can be seen here in Figure 4.   
   Rhamnolipids were also been tested on devices such as voice prostheses and have 
been noted to reduce the initial deposition rates of biofilm after 4h (Rodrigues et al. 2006a).  
A maximum reduction of adhesion (≈66%) was observed when the surfaces such as silicone 
rubber had been preconditioned with rhamnolipids using biofilms of Streptococcus salivarius 
and Candida tropicalis.  The number of cells adhering after 4h was reduced to ≈48% for 
Staphylococcus epidermidis, Streptococcus salivarius, Staphylococcus aureus and C. 
tropicalis in comparison to controls. This group managed to optimise the actions of this 
biosurfactant on the detachment of microorganisms adhering to silicone rubber by perfusing 
the flow chamber with a biosurfactant containing solution followed by passage at the liquid-
air interface. By this method they were able to achieve a high detachment (96%) for most of 
the microbial cells.  
   Rhamnolipids have also been shown to be effective dispersal agents for fungi 
disrupting pre-formed biofilms of Yarrowia lipolytica on glass surfaces by ≈67% which was 
more effective in comparison to the surfactants cetyl-trimethyl ammonium bromide (CTAB) 
and sodium dodecyl sulphate (SDS) (Dusane et al. 2012).  
   It is important to note that although rhamnolipids can effectively disrupt biofilm 
formation and integrity which we observed through phase contrast microscopy where thick 
dense cellular biofilm (Figure 4A) of microcolonies structures on glass coverslips stained 
with crystal violet was much reduced in after treatment with rhamnolipids biosurfactants 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
(Figure 4B). These molecules are also known to be extracellular virulence factors and 
related to the pathogenesis (infection procedure) in Pseudomonas aeruginosa. It has been 
noted that rhamnolipids are also linked to increased lung epithelial permeability, rapid 
necrotic killing of polymorphonuclear leukocytes and the malfunction of normal tracheal 
ciliary motion in the respiratory system of infected patients (Read et al. 1992).   
 
Sophorolipids  
Sophorose lipids are typical glycolipids biosurfactants consisting of a dimer of sophorose 
suger and a long-chain fatty acid that are produced by yeasts belonging to the genus 
Candida.  
   The synergy between sophorolipids and antibiotics has been studied as potential 
strategy to disrupt biofilms  using The LIVE/DEAD BacLight Bacterial Viability Kits as a 
method for detection . This method employs two nucleic acid stains — the green-fluorescent 
SYTO 9® stain and the red-fluorescent propidium iodide stain. These stains differ in their 
ability to penetrate healthy bacterial cells. When used alone, SYTO 9 stain labels both live 
and dead bacteria. In contrast, propidium iodide penetrates only bacteria with damaged 
membranes, reducing SYTO 9 fluorescence when both dyes are present. Thus, live bacteria 
with intact membranes fluoresce green, while dead bacteria with damaged membranes 
fluoresce red. Joshi-Navare and Prabhune (2013) reported the the effect of sophorolipds in 
the disruption of biofilms from Escherichia coli.  Figure 5 illustrated the examination of cells 
of Bacillus subtitlis attached to coverslips after 48h and stained with LIVE/DEAD BacLight 
showing the presence of individual bacteria, small clusters of cells (microcolonies), and 
extended areas of the glass surface covered with large numbers of microcolonies of active 
cells (Figure 5A), as well as, those which their membrane was damage due to the effect of 
sophorolipids 5% (v/v) concentration after 30min of treatment (Figure 5B). 
  
Other Glycolipids as antibiofilm molecules 
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Dusane et al. (2012) reported a glycolipid based on glucose and palmitic acid produced by a 
tropical marine Serratia marcescens was effective in inhibiting biofilms of the marine 
biofouling bacterium Bacillus pumilus and the adhesion of C. albicans and P. aeruginosa 
PAO1.  This effect was also observed with preformed biofilms of these cultures on microtitre 
plate tests.  Other complexes of glycolipids from Brevibacterium casei MSA19 have been 
reported to disrupt and significantly inhibit individual and mixed culture biofilms of human 
and fish  at concentrations of  30 mg/ml (Kiran et al. 2010). 
   Antibiofilm glycolipids have also been isolated from Lactobacillus (Tahmourespour et 
al. 2011; Zakaria Gomaa 2013).  In this case L. paracasei  A20 produced biosurfactants that 
inhibit Gram-positive and Gram-negative bacteria, yeasts and filamentous fungi (Gudina et 
al. 2010). The biosurfactant also showed anti-adhesive activity against pathogenic Candida 
albicans, Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis and 
Streptococcus agalactiae.  Glycolipids derived from plants have also been reported to inhibit 
biofilms.  These include a novel hydroxyproline rich glycopeptide from the pericarp of Datura 
stramonium known as datucin which is also reported to eradicate biofilms of antifungal 
resistant Candida albicans  (Mandal 2012).   
 
Complex surfactant mixtures 
Biosurfactants are seldom found in pure form or isolation and are often associated together 
with isomers or congeners that share similar physiochemical characteristics which makes 
the process of purification either exhaustive or uneconomical.  However these complexes of 
biosurfactants may have the advantage of a broader applicability than pure compounds.  
The same is true of complexes of compounds in other environments; this can be illustrated 
by the large diversity of antimicrobial peptides and surfactants found on the skin of 
amphibians (Bevins and Zasloff 1990). Similarly in innate human defence, antimicrobial 
peptides such as human beta defensins 1 , 2 and 3  and related human neutrophil peptides 
(Ganz et al. 1985) are found in homogenous groups. . 
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   Combinations of biosurfactants have also been extracted from Robinia pseudoacacia 
and Nerium oleander.  These secretions inhibited attachment of biofilms of Candida albicans 
on silicon and denture prosthesis at concentrations of 78μg/ml and 156μg/ml (Cochis et al. 
2012). Other biosurfactants obtained from probiotic bacteria Lactococcus lactis 53 and 
Streptococcus thermophilus greatly reduced microbial numbers on preconditioned voice 
prostheses in an artificial throat model and induced a decrease in the airflow resistance that 
occurs on voice prostheses after biofilm formation (Gakhar et al. 2010). 
 
Biosurfactants from fungi 
Biosurfactants that inhibit biofilms have been found in fungi such as Candida bombicola.  
This produces sophorolipids that inhibit biofilms of V. cholerae (Mukherji and Prabhune 
2014).  Other strains of yeast such as Candida sphaerica have also been reported to 
produce biosurfactants such as Iunasan (Luna et al. 2011). This inhibits the adhesion of 
Pseudomonas aeruginosa, Streptococcus agalactiae and Streptococcus sanguis to levels 
between 80-92%. Similarly rufisan from Candida lypolytica inhibits biofilm formation at 
concentrations greater or equal to 0.75 µg/ml against S. aureus, Streptococcus agalactae, S. 
mutans NS (Rufino et al. 2011). 
 
Mammalian surface active secretions   
From a chemotherapeutical perspective, the most interesting groups of biosurfactants are 
those produced by humans.  Not much is known about these molecules however it has 
recently been reported that PLUNC ("Palate, lung, nasal epithelium clone") protein has anti-
biofilm activity (Gakhar et al. 2010).  These molecules are mainly produced as a secretory 
product of epithelia lining the airways tubes within mammals including humans.  They are 
evolutionarily related to the lipid transfer/lipopolysaccharide binding protein (LT/LBP) family. 
PLUNC are believed to have novel biologically relevant surface active properties as they 
significantly reduce surface tension at the air-liquid interface within aqueous solutions they 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
also inhibited biofilm formation in the airways colonising potential pathogen Pseudomonas 
aeruginosa in vitro at physiologically relevant concentrations (Gakhar et al. 2010).  
 
Conclusions  
 
It has been acknowledged that microbial biofilms lie at the heart of many recalcitrant patient 
infections in the clinical environment, the dissemination of airborne pathogens and the 
fouling of industrial surfaces.  These problems are increasingly exacerbated by the rise of 
resistant biofilm populations and the paucity of alternative eradication solutions. 
Biosurfactants represent an emerging therapy which has inherent anti-bacterial, fungal and 
viral properties with an ability to effectively disperse or disrupt such biofilms.  Their use 
therefore either on their own or as adjuvants to other antimicrobial chemotherapies may 
represent a potential way forward in tackling biofilms in the future.  
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Table 1  Selected biosurfactants reported in literature with antibiofilm/microbial activities. 
___________________________________________________________________________________________________________ 
Biosurfactant class  Name  Source Reference  Effectiveness 
 
Lipopeptide Putisolvin I & II  Pseudomonas 
putida 
Kuiper et al. 2004 Biofilm inhibition of Pseudomonas 
spp.  
Lipopeptide Pseudofactin II  Janek et al. 2010 Effective against E. coli 
Enterococcus faecalis  Proteus 
mirabilis and Candida sp.  
Lipopeptide NS Bacillus subtilis Mireles et al. 2001 Biofilm inhibition of S. entrica on 
urethral catheter 
Lipopeptide Fengycin B. subtilis & B. licheniformis Rivardo et al. 2009 Inhibition of pathogenic E. coli & S. 
entrica 
Lipopeptide NS Heavy metal tolerant strain 
of Bacillus 
Sriram et al. 2011 Inhibits Gram positive and negative 
bacteria and fungi  
Lipopeptide NS Bacillus sp. strain SW9 Wu et al. 2013 Inhibits biofilm formation in a wide 
range of bacteria 
Lipopeptide NS Bacillus tequilensis Pradhan et al. 2013 Biofilm inhibition of E. coli &   
Streptococcus mutans 
Lipopeptide L. fermentum B54 Lactobacillus Velraeds et al. 2000 Inhibits uropathogens 
Glycolipids  NS Brevibacterium casei.  Kiran et al. 2010 Inhibits mixed pathogenic biofilm 
bacteria 
Mixture of biosurfactants Lunasan Candida sphaerica Luna et al. 2011 Inhibition of P. aeruginosa and S. 
agalactae 
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NS NS Lactobacillus 
paracasei A20 
Gudina et al. 2010 Biofilm inhibition for a range of 
bacteria, yeasts & filamentous fungi. 
Glycolipid Rhamnolipid P. aeruginosa Rodrigues et al. 2006b Inhibits biofilms in  
S. aureus 
Candida tropicalis 
Glycolipid Rhamnolipid P. aeruginosa Dusane et al. 2010 Inhibits B. pumulus  
Mixed biosurfactants  Lactococcus lactis  /Strep 
thermophilus 
Rodrigues et al. 2004 
 
Effective against Staphylococcus, 
Streptococcus , Rothia and Candida 
sp.  
NS NS Robinia pseudocacia/ 
Nerium oleander 
Cochis et al. 2012  Effective against C. albicans  
Glycolipids  Rhamnolipid P. aeruginosa Dusane et al. 2012 Effective against Yarrowia sp.  
NS Rufisan Candida lypolytica  Rufino et al. 2011 Effective against Streptococcus sp  
Glycolipid  Glucose + palmitic 
acid 
Serratia Marsecens  Dusane et al. 2011 Effective against C. albicans , P. 
aeruginosa and B. pumilus 
________________________________________________________________________________________________________________  
NS= Not specified 
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Figures legends  
Figure 1.  Calgary Biofilm Device (CBD) measures the minimum biofilm eradication 
concentration (MBEC).  (1) Biofilms cultivated on pegs in 1/10th Muller Hinton broth  
(2) Pegs rinsed with PBS  (3) Pegs exposed to test substances in new wells  (4) 
Pegs rinsed in PBS  (5) Biofilm removed by sonicating pegs into sterile media  (6) 
Remaining viable bacteria in wells is proportional to the biofilm biomass.  
Figure 2.  Biosurfactants: (A) Polymyxin B2,. (B) Fengycin-like peptide, (C)  
Putisolvin II and. (D) Pseudofactin II: 
Figure 3.  Biosurfactants : (A) Surfactin, (B) - Polymyxin D1, (C) Fusaricidin B1,. (D) 
Rhamnolipids: mono rhamnolipid, (l-rhamnosyl-β-hydroxydecanoyl-β-
hydroxydecanoate)(RL-1) and (E)  di-rhamnolipid, (l-rhamnosyl l-rhamnosyl-β-
hydroxydecanoyl-β-hydroxydecanoate (RL-2),  DAB = diaminobutyric acid. 
Figure 4.  Representative images depicting the effect of rhamnolipids on pre-formed 
biofilms of P. aeruginosa PAO1 on cover slips. Cells were stained with crystal violet 
1%, and observed using a phase contrast microscope at 40x. (A) P. aeruginosa 
PAO1 Biofilms after 48h.  (B) After 30min treatment with rhamnolipids (5%) v/v on 
48h biofilms. 
Figure 5.  Biofilm formation by Bacillus subtilis BBK006 on coverslips.  Cells were 
stained with Syto9®, and observed using a fluorescence microscope at 40x. The bar 
represent 100µm . (A) Bacillus subtilis BBK006 biofilms after 48h as a control. (B) 
After 30min treatment in the presence of Sophorolipids 5% v/v on 48h preformed 
biofilms. 
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